Anti-fibrotic effect of intravenous umbilical cord-derived mesenchymal stem cells (Uc-mscs) injection in experimental rats induced liver fibrosis
Sembiring R.J., Sungkar T., Lindarto D., Putra A.
Abstract
Aim To investigate the effect of umbilical cord-derived mesenchymal stem cells (UC-MSCs) administration among liver fibrosis experimental rat model via the regulation of angiotensin II type 1 receptor (AT1R) and platelet-derived growth factor-β (PDGF-β) due to their therapeutic potential to replace liver transplantation for advanced liver fibrosis. Yet the mechanism of action has been questionably associated with UC-MSCs fibrosis regression properties. Methods Sprague-Dawley (SD) rats (n=18) were separated into three groups (control, untreated liver fibrosis, and UC-MSCs treated group). Serum PDGF-β level was determined by enzyme-linked immunosorbent assay (ELISA) following 14 days of UC-MSCs injection. Meanwhile, AT1R expression was interpreted based on immunoreactive score (IRS) stained using polyclonal antibody and liver fibrosis stained with hematoxylin & eosin was graded using the METAVIR score. Results UC-MSCs were isolated successfully from rat umbilical cord. Liver fibrosis was observed following 14 weeks of CCl<inf>4</inf> injection concurrent with higher serum level of PDGF-β, but the UC-MSCs-treated group had lower level (980.08 ±289.41 and 606.42±109.85 for untreated liver fibrosis and UC-MSCs treated group, respectively; p=0.004). There was also a high expression of AT1R among untreated liver fibrosis group, as well as high-grade liver fibrosis versus localized fibrosis and low level of AT1R expression among UC-MSCs treated-group (p=0.001). Conclusion UC-MSCs administration could ameliorate liver fibrosis by reducing the AT1R expression and PDGF-β serum levels, and intervention through this signaling pathway could be alternative evidence for the causative of positive outcome.
Mesenchymal stromal cell therapy for liver diseases
Alfaifi M., Baik S.K., Eom Y.W., Newsome P.N., Alfaifi M., Alfaifi M., Baik S.K., Eom Y.W., Newsome P.N., Newsome P.N., Newsome P.N.
Paracrine effects of adipose-derived stem cells on matrix stiffness-induced cardiac myofibroblast differentiation via angiotensin II type 1 receptor and smad7
Gao B., Gao B., Huang G., Li Y., Liu F., Lu T.J., Ma Y., Pingguan-Murphy B., Wan Abas W.A.B., Wan Safwani W.K.Z., Xu F., Yong K.W., Yong K.W.
Cytokines and Renin-Angiotensin System Signaling in Hepatic Fibrosis
Bataller R., Moreno M.
Angiotensin II enhances epithelial-to-mesenchymal transition through the interaction between activated hepatic stellate cells and the stromal cell-derived factor-1/CXCR4 axis in intrahepatic cholangiocarcinoma
Fujimura T., Fujita H., Fushida S., Harada S., Hayashi H., Iseki S., Kinoshita J., Kitagawa H., Makino I., Nakagawara H., Nakamura K., Nakanuma S., Ninomiya I., Ohta T., Okamoto K., Oyama K., Sakai S., Tajima H., Takamura H., Wakayama T.
The role of the renin-angiotensin system in liver fibrosis
Glaser S.S., Glaser S.S., Glaser S.S., Munshi M.K., Uddin M.N.
Mesenchymal stem cells accelerate liver regeneration in acute liver failure animal model
Agung P., Antari A.D., Kustiyah A.R., Nurintan Y.S., Sadyah N.C., Wirawan N., Anna C, Antari A, Putra A, RetnoKustiyah A, Sadyah N, SorayaNurIn-tan Y, Wirawan N., Antari AD, Intan YSN, Kustiyah AR, Putra A, Sadyah NAC, Wirawan N, Antari AD, Astarina S, Intan YSN, Kustiyah AR, Munir D., Putra A, Sadyah NAC, Wirawan N, Zubir N
Human umbilical cord mesenchymal stem cells inhibit proliferation of hepatic stellate cells in vitro
Chen H., Fang X.-Q., Li J.F., Mao X.R., Peng X-B., Zhang L.-T.
Concise review on clinical applications of conditioned medium derived from human umbilical cord-mesenchymal stem cells (UC-MSCS)
Banerjee A., Di Liddo R., Gopinath M., Jothimani G., Marotta F., Marotta F., Murugesan R., Pathak S., Sriramulu S.
Use of mesenchymal stem cells to treat liver fibrosis: Current situation and future prospects
Berardis S., Najimi M., Sattwika P.D., Sokal E.M., Berardis S., Najimi M., Sattwika P.D., Sokal E.M., Berardis S., Najimi M., Sattwika P.D., Sokal E.M.
Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets
Ezhilarasan D., Najimi M., Sokal E.
